PDL BioPharma Inc

PDL BioPharma — Q3 2018 Earnings Presentation

11 slides from PDL BioPharma's earnings presentation, Nov 6, 2018

  1. Slide 1: Third Quarter 2018 Financial Results Conference Call

    PDL Third Quarter 2018 Financial Results Conference Call November 6, 2018

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements, including PDL's expectations with respectto its future royalty revenues, expenses, net income, and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actua

  3. Slide 3: Assertio (Depomed) Royalties — Amended Agreement

    Assertio (Depomed) Royalties — Amended Agreement Q Original agreement: = In October 2013, PDL paid $240.5 million for 100% of royalties and milestones on sales of type 2 diabetes products until cash flows reached $481 million (two times original investment) after which proceeds would be split evenly

  4. Slide 4: Share Repurchase Programs

    Share Repurchase Programs a Completed a $25 million program in July 2018 = Since March 2017, we have repurchased 22.1 million shares for a total of $55.0 million. = Average repurchase share price of $2.49. = 146.0 million shares outstanding as of October 30, 2018. a Announced a new $100 million shar

  5. Slide 5: Q3 Increase in Royalty Rights Fair Value Results in Book Value Increase

    Q3 18 Increase in Royalty Rights Fair Value Results in a Book Value Increase of $0.22 vs. Prior Quarter PDL’s book value for the period ending September 30, 2018 was $5.07 PDL's Book Value Per Share RSASRSASRSaShSa SSSPREENNNNUWWW REREAD Roa Pyeyspenspeyspepsrerspays asa 4 4 4 4 Ss 5 5 5 6 16 6 6 7

  6. Slide 6: Business Development Strategy Details

    @ Business Development Strategy Details Q Pursuing transactions that: = Generate profitable revenue growth; = Deliver attractive risk/reward returns on our invested capital; and « Leverage our expertise in the biopharma space. QO Pursuing the following key categories: = Products or companies that ha

  7. Slide 7: Noden: Focus on Profitability

    Noden: Focus on Profitability a Reported revenues on the Noden products for Q318 of $17.8 million. = $9.7 million from U.S. sales and $8.1 million from ROW. a No update on Anchen’s progress in developing a generic aliskiren. a Noden planning an authorized generic version of Tekturna that will allow

  8. Slide 8: LENSAR Update

    LENSAR Update a LENSAR reported revenues of $6.6 million in Q3 2018. = 33 percent increase in product revenues over Q3 2017. = 13 percent increase over Q2 2018. a Q3 2018 GAAP net loss of approx. $900,000. » Effectively break-even on an EBITDA basis. Q 7 LENSAR Laser Systems sold in Q3 2018.

  9. Slide 9: Financials

    Third Quarter 2018 Financials ‘Three Months Ended Nine Months Ended September 30, September 30, (In thousands, except per share amounts) 2018 2017 2018 2017 Royalties from Queen et al. patents S533 $ 1443 § 4534 § 31,864 Royalty rights - change in fair value 42.184 35,353 66117 132,224 Interest reve

  10. Slide 10: Financials

    10 Third Quarter 2018 Financials GAAP net income (loss) attributed to PDL’s shareholders as reported Adjustments Mark-to-market adjustment to fair value assets Non-cash interest revenues Non-cash stock-based compensation expense Non-cash debt offering costs Mark-to-market adjustment on warrants held

  11. Slide 11: Financials

    Third Quarter 2018 Financials Condensed consolidated balance sheet (unaudited) Cash, cash equivalents and investments Total notes receivable Royalty rights - at fair value Intangible assets, net Total assets Convertible notes payable Total stockholders's equity September 30, June 30, December 31, 20

PDL BioPharma — Q3 2018 Earnings Presentation on 6ix